SG11201500412TA - Vaccine compositions - Google Patents

Vaccine compositions

Info

Publication number: SG11201500412TA
Authority: SG; Singapore
Prior art keywords: vaccine compositions; vaccine; compositions
Prior art date: 2012-07-24

Application number

SG11201500412TA

Inventor

Alain Bouckenooghe

Remi Forrat

Jean Lang

Mélanie Saville

Nadia Tornieporth

Original Assignee

Sanofi Pasteur

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-07-24

Filing date

2013-07-24

Publication date

2015-02-27

2013-07-24 Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur

2015-02-27 Publication of SG11201500412TA publication Critical patent/SG11201500412TA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Immunology (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

SG11201500412TA 2012-07-24 2013-07-24 Vaccine compositions SG11201500412TA (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP12305907		2012-07-24
EP12305912		2012-07-25
PCT/EP2013/065667 WO2014016360A1 (en)	2012-07-24	2013-07-24	Vaccine compositions

Publications (1)

Publication Number	Publication Date
SG11201500412TA true SG11201500412TA (en)	2015-02-27

Family

ID=48875047

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG10201912291YA SG10201912291YA (en)	2012-07-24	2013-07-24	Vaccine compositions
SG11201500412TA SG11201500412TA (en)	2012-07-24	2013-07-24	Vaccine compositions

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SG10201912291YA SG10201912291YA (en)	2012-07-24	2013-07-24	Vaccine compositions

Country Status (12)

Country	Link
US (2)	US20150196631A1 (en)
EP (2)	EP3932422A1 (en)
JP (2)	JP2015524421A (en)
KR (2)	KR20200067938A (en)
CN (1)	CN104812407B (en)
AU (1)	AU2013295014B2 (en)
CA (1)	CA2878682A1 (en)
MX (2)	MX381497B (en)
MY (2)	MY168959A (en)
PH (1)	PH12014502840B1 (en)
SG (2)	SG10201912291YA (en)
WO (1)	WO2014016360A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2013295016A1 (en) *	2012-07-24	2015-01-29	Sanofi Pasteur	Vaccine compositions for prevention against dengue virus infection
CA2903231A1 (en)	2013-03-15	2014-09-25	Takeda Vaccines, Inc.	Compositions and methods for dengue virus chimeric constructs in vaccines
TWI852899B (en)	2014-09-02	2024-08-21	法商賽諾菲巴斯德公司	Vaccine compositions
CN107405392B (en) *	2015-02-09	2021-05-18	中央研究院	Epitope-replaced vaccine for enhanced safety and immunity against dengue virus
BR112017028212A2 (en) *	2015-07-03	2018-09-11	Sanofi Pasteur	concomitant vaccination against dengue and yellow fever
EP3147294B1 (en) *	2015-09-24	2020-04-29	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Distinguishing dengue virus infections from other flaviviral infections using a recombinant mutant envelope protein
JP6910956B2 (en) *	2015-11-27	2021-07-28	Ｋｍバイオロジクス株式会社	Live viruses banked from attenuated dengue virus strains and dengue vaccines using them as antigens
CN109069615B (en) *	2016-04-13	2025-03-04	武田疫苗股份有限公司	Compositions and methods for vaccination against dengue virus in children and young adults
WO2018208741A1 (en)	2017-05-08	2018-11-15	University Of Pittsburgh-Of The Commonwealth System Of Higher Education	Methods and compositions for the detection of flavivirus infections
EP3691681A1 (en) *	2017-10-05	2020-08-12	Sanofi Pasteur	Compositions for booster vaccination against dengu
WO2019113285A2 (en)	2017-12-06	2019-06-13	Emory University	Zika vaccines and methods of use
EP3549603A1 (en)	2018-04-06	2019-10-09	Sanofi Pasteur	Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same
US11464815B2 (en)	2018-09-05	2022-10-11	Takeda Vaccines, Inc.	Dengue vaccine unit dose and administration thereof
AU2019335006B2 (en)	2018-09-05	2024-07-04	Takeda Vaccines, Inc.	Dengue vaccine unit dose and administration thereof
US11426461B2 (en)	2018-09-05	2022-08-30	Takeda Vaccines, Inc.	Methods for preventing dengue and hepatitis A
CN112079934B (en) *	2019-12-17	2021-01-29	合源生物科技(天津)有限公司	Chimeric antigen receptor targeting CD19 and application thereof
CN116334070A (en) *	2023-02-15	2023-06-27	天津大学	Application of fusion protein and method of cell fusion

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US109A (en)		1836-12-15		Erawijtg
US5422A (en)		1848-02-01		Spark-arrester
WO1990014837A1 (en)	1989-05-25	1990-12-13	Chiron Corporation	Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649012B1 (en)	1989-07-03	1991-10-25	Seppic Sa	INJECTABLE MULTIPHASIC EMULSIONS
FR2649013B1 (en)	1989-07-03	1991-10-25	Seppic Sa	VACCINES AND VECTORS OF FLUID ACTIVE INGREDIENTS CONTAINING METABOLIZABLE OIL
GB9326253D0 (en)	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
US6254873B1 (en)	1995-04-17	2001-07-03	The United States Of America As Represented By The Secretary Of The Army	Inactivated dengue virus vaccine
WO1996040933A1 (en)	1995-06-07	1996-12-19	The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services	Infectious dengue 2 virus pdk-53 as quadravalent vaccine
AU740961B2 (en)	1997-02-28	2001-11-15	Sanofi Pasteur Biologics Co.	Chimeric flavivirus vaccines
GB9711990D0 (en)	1997-06-11	1997-08-06	Smithkline Beecham Biolog	Vaccine
WO1999011241A1 (en)	1997-09-05	1999-03-11	Smithkline Beecham Biologicals S.A.	Oil in water emulsions containing saponins
GB9718901D0 (en)	1997-09-05	1997-11-12	Smithkline Beecham Biolog	Vaccine
CA2365728A1 (en)	1999-03-26	2000-10-05	Walter Reed Army Institute Of Research	Attenuated dengue-1 virus vaccine
WO2000057904A2 (en)	1999-03-26	2000-10-05	Walter Reed Army Institute Of Research	Attenuated dengue-3 virus vaccine
WO2000057910A1 (en)	1999-03-26	2000-10-05	Walter Reed Army Institute Of Research	Attenuated dengue-4 virus vaccine
AU4040200A (en)	1999-03-26	2000-10-16	Walter Reed Army Institute Of Research	Attenuated dengue-2 virus vaccine
AU3844101A (en)	2000-02-16	2001-08-27	Us Health	Avirulent, immunogenic flavivirus chimeras
PT1159968E (en)	2000-05-30	2008-11-20	Univ Mahidol	Attenuated strains of dengue virus and their use in a vaccine composition
AT410634B (en)	2001-02-21	2003-06-25	Franz X Dr Heinz	ATTENUATED LIFE VACCINE
EP2290108B1 (en)	2001-05-22	2014-07-23	THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES	Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
KR20040004642A (en)	2001-05-23	2004-01-13	덴드레온 샌 디에고 엘엘씨	Conjugates activated by cell surface proteases and therapeutic uses thereof
CN1551782A (en)	2001-06-01	2004-12-01	��ķ��	Chimeric flavivirus vectors
CA2473321C (en) *	2002-01-15	2015-10-06	Acambis, Inc.	Flavivirus vaccines
AU2003239932A1 (en) *	2002-05-31	2003-12-19	Acambis, Inc.	Tetravalent dengue vaccines
BRPI0613328A2 (en) *	2005-06-17	2011-01-04	Sanofi Pasteur	live attenuated dengue-1 virus strain, immunogenic composition, vaccine composition, isolated nucleic acid, isolated polyprotein and polyprotein fragment
CA2611954C (en)	2005-06-17	2014-01-28	Sanofi Pasteur	Dengue serotype 2 attenuated strain
AR054822A1 (en)	2005-07-07	2007-07-18	Sanofi Pasteur	ADMISSION IMMUNE EMULSION
BRPI0614265A2 (en)	2005-08-10	2011-03-22	Acambis Inc	use of a yellow fever virus vaccine and a chimeric flavivirus vaccine and kit containing such vaccines
JP5138601B2 (en) *	2005-11-21	2013-02-06	サノフィパストゥールリミテッド	Recombinant virus stabilization formulation
US7968102B2 (en) *	2006-01-13	2011-06-28	Sanofi Pasteur S.A.	Dengue chimeric viruses
FR2896162B1 (en)	2006-01-13	2008-02-15	Sanofi Pasteur Sa	EMULSION OIL IN THERMOREVERSIBLE WATER
FR2903605A1 (en)	2006-07-12	2008-01-18	Sanofi Pasteur Sa	IMMUNIZATION METHOD AGAINST THE FOUR SEROTYPES OF DENGUE
FR2906724B1 (en) *	2006-10-04	2009-03-20	Sanofi Pasteur Sa	METHOD OF IMMUNIZATION AGAINST THE 4 SEROTYPES OF DENGUE.
FR2909286B1 (en)	2006-12-01	2012-06-08	Sanofi Pasteur	IMMUNIZATION METHOD AGAINST THE 4 SEROTYPES OF DENGUE
EP2143440A1 (en)	2008-07-09	2010-01-13	Sanofi Pasteur	Stabilising agent and vaccine composition comprising one or several attenuated living flavivirus
GB201007531D0 (en)	2010-05-05	2010-06-23	Imp Innovations Ltd	Composition

2013
- 2013-07-24 MY MYPI2014003501A patent/MY168959A/en unknown
- 2013-07-24 CA CA2878682A patent/CA2878682A1/en active Pending
- 2013-07-24 KR KR1020207016038A patent/KR20200067938A/en not_active Ceased
- 2013-07-24 EP EP21173406.6A patent/EP3932422A1/en active Pending
- 2013-07-24 WO PCT/EP2013/065667 patent/WO2014016360A1/en active Application Filing
- 2013-07-24 MY MYPI2018700631A patent/MY197723A/en unknown
- 2013-07-24 CN CN201380049627.XA patent/CN104812407B/en active Active
- 2013-07-24 AU AU2013295014A patent/AU2013295014B2/en active Active
- 2013-07-24 JP JP2015523548A patent/JP2015524421A/en not_active Ceased
- 2013-07-24 SG SG10201912291YA patent/SG10201912291YA/en unknown
- 2013-07-24 US US14/416,496 patent/US20150196631A1/en not_active Abandoned
- 2013-07-24 KR KR20157003821A patent/KR20150036592A/en not_active Ceased
- 2013-07-24 EP EP13741748.1A patent/EP2877208B1/en active Active
- 2013-07-24 MX MX2015000442A patent/MX381497B/en unknown
- 2013-07-24 SG SG11201500412TA patent/SG11201500412TA/en unknown
2014
- 2014-12-19 PH PH12014502840A patent/PH12014502840B1/en unknown
2015
- 2015-01-09 MX MX2021004211A patent/MX2021004211A/en unknown
2018
- 2018-09-06 US US16/123,319 patent/US20190201517A1/en not_active Abandoned
2019
- 2019-04-03 JP JP2019071529A patent/JP6830118B2/en active Active

Also Published As

Publication number	Publication date
AU2013295014B2 (en)	2018-01-18
JP2019151636A (en)	2019-09-12
MX2021004211A (en)	2021-05-27
JP2015524421A (en)	2015-08-24
US20150196631A1 (en)	2015-07-16
EP2877208B1 (en)	2021-05-12
EP3932422A1 (en)	2022-01-05
CN104812407A (en)	2015-07-29
PH12014502840A1 (en)	2015-02-23
SG10201912291YA (en)	2020-02-27
MY197723A (en)	2023-07-10
JP6830118B2 (en)	2021-02-17
WO2014016360A1 (en)	2014-01-30
MY168959A (en)	2019-01-28
CA2878682A1 (en)	2014-01-30
KR20150036592A (en)	2015-04-07
PH12014502840B1 (en)	2015-02-23
MX2015000442A (en)	2015-03-12
KR20200067938A (en)	2020-06-12
US20190201517A1 (en)	2019-07-04
AU2013295014A1 (en)	2015-01-29
MX381497B (en)	2025-03-12
CN104812407B (en)	2022-11-22
EP2877208A1 (en)	2015-06-03
HK1212906A1 (en)	2016-06-24

Publication	Publication Date	Title
PL2647387T3 (en)	2016-09-30	Vaccine Composition
SG11201500412TA (en)	2015-02-27	Vaccine compositions
GB201223386D0 (en)	2013-02-06	Vaccine
IL237431A0 (en)	2015-04-30	Immunogenic compositions
IL233649A0 (en)	2014-08-31	Chitosan-derived compositions
GB2511197B (en)	2017-05-03	Compositions
GB201210800D0 (en)	2012-08-01	Compositions
ZA201503157B (en)	2016-01-27	Compositions
GB201209244D0 (en)	2012-07-04	Compositions
GB201201287D0 (en)	2012-03-07	Compositions
ZA201503062B (en)	2016-01-27	Compositions
GB201220068D0 (en)	2012-12-19	Compositions
GB201210226D0 (en)	2012-07-25	Vaccine
GB201202090D0 (en)	2012-03-21	Vaccine
ZA201502542B (en)	2016-11-30	Compositions
GB201219980D0 (en)	2012-12-19	Compositions
GB201219973D0 (en)	2012-12-19	Compositions
GB201219962D0 (en)	2012-12-19	Compositions
TWI561248B (en)	2016-12-11	Peracid-generating compositions
EP2926813A4 (en)	2016-05-25	Metformin-orlistat compositions
GB201223148D0 (en)	2013-02-06	Compositions
GB201222702D0 (en)	2013-01-30	Compositions
GB201218959D0 (en)	2012-12-05	Compositions
GB201209189D0 (en)	2012-07-04	Compositions
GB201209187D0 (en)	2012-07-04	Compositions